Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2025)

Historic Operating Leases for Xeris Biopharma Holdings (XERS) over the last 4 years, with Q3 2025 value amounting to $38.2 million.

  • Xeris Biopharma Holdings' Operating Leases fell 377.01% to $38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year decrease of 377.01%. This contributed to the annual value of $33.3 million for FY2024, which is 432.92% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Operating Leases of $38.2 million as of Q3 2025, which was down 377.01% from $38.6 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Operating Leases high stood at $39.7 million for Q3 2024, and its period low was $9.4 million during Q4 2022.
  • In the last 4 years, Xeris Biopharma Holdings' Operating Leases had a median value of $37.9 million in 2023 and averaged $33.0 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Operating Leases soared by 26975.11% in 2023 and then tumbled by 432.92% in 2024.
  • Xeris Biopharma Holdings' Operating Leases (Quarter) stood at $9.4 million in 2022, then skyrocketed by 269.75% to $34.8 million in 2023, then dropped by 4.33% to $33.3 million in 2024, then grew by 14.81% to $38.2 million in 2025.
  • Its last three reported values are $38.2 million in Q3 2025, $38.6 million for Q2 2025, and $39.0 million during Q1 2025.